Relationship between endothelial dysfunction, oxidant stress and aspirin resistance in patients with stable coronary heart disease

Journal of Clinical Pharmacy and Therapeutics

Volumn 32, Issue 3, 2007, Pages 287-292

  Cheng, G ^a   Shan, J ^a   Xu, G ^a   Liu, P ^a   Zhou, Y ^a   Zhu, Y ^a   Lu, X ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Aspirin; Endothelial dysfunction; Oxidative stress; Platelets

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ALPHA TOCOPHEROL; ASCORBIC ACID; BIOLOGICAL MARKER; LIPID PEROXIDE; SUPEROXIDE DISMUTASE; THROMBOMODULIN; TISSUE FACTOR PATHWAY INHIBITOR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DRUG ACTIVITY; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; STATISTICAL SIGNIFICANCE; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; VITAMIN BLOOD LEVEL;

ADENOSINE DIPHOSPHATE; AGED; AGED, 80 AND OVER; ASCORBIC ACID; ASPIRIN; BIOLOGICAL MARKERS; CORONARY DISEASE; DRUG RESISTANCE; ENDOTHELIUM, VASCULAR; ERYTHROCYTES; FEMALE; HUMANS; LIPID PEROXIDES; LIPOPROTEINS; MALE; MIDDLE AGED; OXIDATIVE STRESS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; SUPEROXIDE DISMUTASE; THROMBOMODULIN; VITAMIN E;

EID: 34247897084     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2007.00823.x     Document Type: Article

References (32)

1. Gum PA, Kottke-Marchant K, Poggio ED et al. (2001) Profile and prevalence of aspirin resistance in patients with cardiovascular disease. The American Journal of Cardiology, 88, 230 235.
2. Lev EI, Patel RT, Maresh KJ et al. (2006) Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. Journal of the American College of Cardiology, 47, 27 33.
3. Weber AA, Zimmermann KC, Meyer-Kirchrath J, Schror K (1999) Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance. Lancet, 353, 900.
4. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S (2002) Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation, 105, 1650 1655.
5. Mano T, Masuyama T, Yamamoto K et al. (1996) Endothelial dysfunction in the early stage of atherosclerosis precedes appearance of intimal lesions assessable with intravascular ultrasound. American Heart Journal, 131, 231 238.
6. Halcox JP, Schenke WH, Zalos G et al. (2002) Prognostic value of coronary vascular endothelial dysfunction. Circulation, 106, 653 658.
7. Cerwinka WH, Cooper D, Krieglstein CF, Feelisch M, Granger DN (2002) Nitric oxide modulates endotoxin-induced platelet-endothelial cell adhesion in intestinal venules. American Journal of Physiology. Heart and Circulatory Physiology, 282, H1111 H1117.
8. Ouvina SM, La Greca RD, Zanaro NL, Palmer L, Sassetti B (2001) Endothelial dysfunction, nitric oxide and platelet activation in hypertensive and diabetic type II patients. Thrombosis Research, 102, 107 114.
9. Andrews NP, Husain M, Dakak N, Quyyumi AA (2001) Platelet inhibitory effect of nitric oxide in the human coronary circulation: impact of endothelial dysfunction. Journal of the American College of Cardiology, 37, 510 516.
10. Nokes TJ, Mahmoud NA, Savidge GF et al. (1984) Von Willebrand factor has more than one binding site for platelets. Thrombosis Research, 34, 361 366.
11. Massberg S, Enders G, Leiderer R et al. (1998) Platelet-endothelial cell interactions during ischemia/reperfusion: the role of P-selectin. Blood, 92, 507 515.
12. O'Brien KD, Alpers CE, Hokanson JE, Wang S, Chait A (1996) Oxidation-specific epitopes in human coronary atherosclerosis are not limited to oxidized low-density lipoprotein. Circulation, 94, 1216 1225.
13. Li Z, Mao HZ, Abboud FM, Chapleau MW (1996) Oxygen-derived free radicals contribute to baroreceptor dysfunction in atherosclerotic rabbits. Circulation Research, 79, 802 811.
14. Cai H, Harrison DG (2000) Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circulation Research, 87, 840 844.
15. Cipollone F, Ciabattoni G, Patrignani P et al. (2000) Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina. Circulation, 102, 1007 1013.
16. Zhou JF, Yan XF, Guo FZ, Sun NY, Qian ZJ, Ding DY (2000) Effects of cigarette smoking and smoking cessation on plasma constituents and enzyme activities related to oxidative stress. Biomedical and Environmental Sciences, 13, 45 55.
17. Cipollone F, Toniato E, Martinotti S et al. (2004) Gene as an inherited protective factor against myocardial infarction or stroke. The Journal of the American Medical Association, 2, 2221 2228.
18. Michelson AD, Furman MI, Goldschmidt-Clermont P et al. (2000) Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists. Circulation, 101, 1013 1018.
19. Macchi L, Christiaens L, Brabant S et al. (2003) Resistance in vitro to low-dose aspirin is associated with platelet PlA1 (GP IIIa) polymorphism but not with C807T(GP Ia/IIa) and C-5T Kozak (GP Ibalpha) polymorphisms. Journal of the American College of Cardiology, 42, 1115 1119.
20. Kurth T, Glynn RJ, Walker AM et al. (2003) Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation, 108, 1191 1195.
21. Catella-Lawson F, Reilly Kapoor SC, Cuchiara AJ et al. (2001) Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. The New England Journal of Medicine, 345, 1809 1817.
22. Lee PY, Chen WH, Ng W et al. (2005) Low-dose aspirin increases aspirin resistance in patients with coronary artery disease. The American Journal of Medicine, 118, 723 727.
23. Pulcinelli FM, Pignatelli P, Celestini A, Riondino S, Gazzaniga PP, Violi F (2004) Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients. Journal of the American College of Cardiology, 43, 979 984.
24. Morange PE, Simon C, Alessi MC et al. (2004) Endothelial cell markers and the risk of coronary heart disease: the Prospective Epidemiological Study of Myocardial Infarction (PRIME) study. Circulation, 109, 1343 1348.
25. Perez-Jimenez F, Castro P, Lopez-Miranda J et al. (1999) Circulating levels of endothelial function are modulated by dietary monounsaturated fat. Atherosclerosis, 145, 351 358.
26. Broze GJ Jr. (1995) Tissue factor pathway inhibitor. Thrombosis and Haemostasis, 74, 90 93.
27. Sadler JE (1997) Thrombomodulin structure and function. Thrombosis and Haemostasis, 78, 392 395.
28. Dole VS, Bergmeier W, Mitchell HA, Eichenberger SC, Wagner DD (2005) Activated platelets induce Weibel-Palade-body secretion and leukocyte rolling in vivo: role of P-selectin. Blood, 106, 2334 2339.
29. Loscalzo J (2001) Nitric oxide insufficiency, platelet activation, and arterial thrombosis. Circulation Research, 88, 756 762.
30. Schafer A, Alp NJ, Cai S et al. (2004) Reduced vascular NO bioavailability in diabetes increases platelet activation in vivo. Arteriosclerosis, Thrombosis, and Vascular Biology, 24, 1720 1726.
31. Cooper D, Stokes KY, Tailor A, Granger DN (2002) Oxidative stress promotes blood cell-endothelial cell interactions in the microcirculation. Cardiovascular Toxicology, 2, 165 180.
32. Csiszar A, Stef G, Pacher P, Ungvari Z (2002) Oxidative stress-induced isoprostane formation may contribute to aspirin resistance in platelets. Prostaglandins, Leukotrienes, and Essential Fatty Acids, 66, 557 558.